Abbott Laboratories (ABT) News 38.31 $ABT
Abbott Announces FDA Approval of Its Supera® Stent to Treat People with Peripheral Artery Disease
PR Newswire - Fri Mar 28, 10:58AM CDT
Abbott today announced that its Supera® Peripheral Stent System has received U.S. Food and Drug Administration (FDA) approval to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). PAD occurs when fat and cholesterol buildup causes arteries outside of the heart to narrow, which reduces blood flow to parts of the body, most commonly the legs. The disease affects 12 to 20 percent of Americans age 65 or older and can cause leg pain, in addition to increasing the risk of heart attack or stroke.1
Baxter Hits 52-Week High on Planned Business Split-Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 9:24AM CDT
BAX expects to complete splitting up the business in mid-2015
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Baxter Splitting In Effort To 'Unlock Trapped Value'
at Investor's Business Daily - Thu Mar 27, 5:41PM CDT
Baxter International (BAX) announced Thursday that it will split its biopharma and medical-products businesses into two separate companies by mid-2015, jump-starting its lagging stock with a move that seemed to surprise Wall Street. "We and many...
Baxter splitting into 2 separate businesses
By LINDA A. JOHNSON - AP - Thu Mar 27, 1:32PM CDT
TRENTON, N.J. (AP) — Following a rival's lead, Baxter International Inc. said it's planning a breakup into two health care companies as it tries to boost innovation and profitability and reward shareholders.
Baxter International to Split In Response to Macro Challenges
at The Street - Thu Mar 27, 7:05AM CDT
Baxter International's split was also characterized as a response to diverging dynamics between the two businesses and a rapidly changing macro-environment.
Abbott Laboratories (ABT) Crosses Pivot Point Resistance at $38.71
Comtex SmarTrend(R) - Wed Mar 26, 10:44AM CDT
Shares of Abbott Laboratories (NYSE:ABT) have bullishly opened above the pivot of $38.39 today and have reached the first resistance level of $38.71. Analysts will be watching for a cross of the next upside pivot targets of $39.01 and $39.63.
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Is J&J's Forgotten Half About to Take Off?
Peter Stephens, The Motley Fool - Motley Fool - Tue Mar 25, 5:30PM CDT
Johnson & Johnson is often cited as the biggest pharmaceutical company in the world, but it also generates a significant amount of revenue from medical device products. Let's take a deep dive into this division and focus on the key areas that...
RBCC to Increase Investment in 3D Bioprinting Innovation
Business Wire - Tue Mar 25, 9:18AM CDT
As demand for new cellular research innovations continues to soar worldwide, Rainbow Biosciences, the biotechnology division of Rainbow Coral Corp. (OTCBB: RBCC), is increasing its investment in the marketing and development of a breakthrough 3D bioprinting technology.
The Global Generic Drugs Industry Experienced Average Growth Over the Last Five Years and is Expected to Reach Approximately US $335.8 Billion in 2017
M2 - Tue Mar 25, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2st8r/top_five_generic) has announced the addition of the "Top Five Generic Drugs Companies: Performance, Strategies and Competitive Analysis" report to their offering. Top companies are making strategic acquisitions to expand their global footprint, together with taking advantage of established business and expertise gained through the acquired company. The report provides detailed insight into the performance of the top five generic drug companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered. The fragmented generic drugs industry includes producers of medications whose patent or marketing rights have expired. The industry includes drugs from all therapeutic areas: central nervous system, cardiovascular drugs, oncology drugs, and others. A combination of factors such as technology innovations, patent expiration, aging population, and changing lifestyles substantially affect market dynamics. In this study, the author profiles the following five companies with detailed competitive assessments: - Abbott Laboratories - Novartis AG - Mylan Inc. - Teva Pharmaceuticals Ind. Ltd. - Watson Pharmaceuticals Inc As indicated in the study, the Asia Pacific (APAC) region holds good growth potential. India is expected to play an increasing role in the global economy as demand from a growing population continues to drive consumption for generic drugs. Major pharmaceuticals companies are planning to invest in the Asian markets to gain the market share for generic drugs. This study provides industry leaders with a competitive benchmarking of the world's top five generic drug companies. The study provides up-to-date information on the market share, profit margins, capabilities, and business strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis, and insight, critical to the development and implementation of effective marketing and sales plans. For more information visit http://www.researchandmarkets.com/research/q2...ve_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Top Five Global Medical Device Companies: The Global Medical Device Industry is Expected to Reach Approximately $302 Billion in 2017 with A CAGR of 6.1% over Next Five Years
M2 - Tue Mar 25, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl6bwk/top_five_global) has announced the addition of the "Top Five Global Medical Device Companies: Performance, Strategies and Competitive Analysis" report to their offering. The report provides detailed insight into the performance of the top five medical devices companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered. The medical device industry is highly fragmented and consists of surgical and infection control devices, general medical devices, cardiovascular, home healthcare, and other devices. North America dominates this industry. In this study, the author thoroughly profiles the following five companies with detailed competitive assessments: - Abbott Laboratories - Boston Scientific - Covidien Plc. - Johnson & Johnson - Medtronic, Inc. The research indicates that technological advancement, growing population, and increasing aging population is expected to provide opportunities for the industry players. Technology advancement may lead to nanotechnology applications and use of surgical robots as a new segment entering into the medical device industry, and this is further expected to improve the prospects for the device market. India and China are expected to be the driving countries for growth. North America is expected to witness a considerable growth for the medical device industry over the forecast period. The cardiovascular segment represents good growth during the forecast period. This study is intended to provide industry leaders with a concise overview of the world's top five global medical equipment companies. This discussion is limited to a comparative analysis of the subject companies, their geographic footprints, financial metrics, market performance, marketing and corporate strategies, and SWOT analysis. It excludes the equipment such as orthopedic, invitro diagnostic, technical aids, and such other equipment. For more information visit http://www.researchandmarkets.com/research/cl...ive_global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT November 22nd Options Begin Trading
at The Street - Mon Mar 24, 11:09AM CDT
Investors in Abbott Laboratories saw new options become available today, for the November 22nd expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 243 days until expiration the...
This Generic Drug Threat Won't Go Away
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Mar 22, 12:35PM CDT
Editor's Note: In the video, Michael Douglass refers to a quote from Mylan's president. The quote is actually from the president of Mylan's North American operations, Anthony Mauro. The Fool regrets the error. "The unintended consequences of...
China Adalimumab Market Investigation Report with 2018 Forecasts Now Available at ChinaMarketResearchReports.com
PRWeb - Fri Mar 21, 9:31PM CDT
Adalimumab is a TNF (tumor necrosis factor) inhibiting antiinflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA.
After Yesterday's Decline of 1.44%, Abbott Laboratories Offers Investors Better Value
Comtex SmarTrend(R) - Thu Mar 20, 3:54PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $38.78 to a high of $39.64. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $39.04 on volume of 10.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Sucampo's NDA Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:05PM CDT
Sucampo Pharma recently announced that its New Drug Application (NDA) for the liquid formulation of Amitiza will not be filed in the second half of 2014.
Drug Device Combination Products Market Report 2013 - 2019: Forecasts & Trends for the $US100 Billion Market
M2 - Tue Mar 18, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wmt3kk/drug_device) has announced the addition of the "Drug Device Combination Products Market Report 2013 - 2019: Forecasts & Trends for the $US100 Billion Market" report to their offering. The global drug device combination products market was valued at USD 66 billion in 2012 and is expected to grow at a CAGR of 7.9% from 2013 to 2019, to reach an estimated value of USD 115 billion in 2019. This report studies the global market for drug device combination products from the perspective of product types. The market is thus segmented into drug eluting stents, infusion pumps, bone graft implants, photodynamic therapy, wound care combination devices, inhalers, transdermal patches and others including intraocular implants and drug eluting beads. The market for all these product segments is also analyzed for four major geographic regions namely North America, Europe, Asia and the rest of the world (RoW) regions. The markets for all these segments is analyzed and estimated in USD billion. Each of the segments have been analyzed on the basis of its current and future market size for the period 2011 to 2019, in terms of revenue generation in USD billion, considering 2011 and 2012 as the base years. The compounded annual growth rate (%CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. A competitive landscape, mapping all the market players and their respective market shares for 2012 are provided in this report for drug eluting stents and infusion pumps. A chapter on recommendations for existing and new entrants is also provided in this report. Drug Device Combination Products Market: - Drug Eluting Stents - Infusion Pumps - Photosensitizers - Orthopedic Combination Products - Wound Care Combination Products - Inhalers - Transdermal Patches - Intraocular Implants and Drug Eluting Beads Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Drug Device Combination Products, by Type, Size and Forecast, 2011-2019 (USD Billion) Chapter 5 Global Drug Device Combination Products, by Geography, 2011 - 2019 (USD Million) Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories - Alcon, Inc. - Allergan, Inc. - Arrow International, Inc. - Bausch & Lomb, Inc. - Boston Scientific Corporation - C.R. Bard, Inc. - CareFusion Corporation - Covidien PLC - Ethicon, Inc. - Medline Industries, Inc. - Medtronic, Inc. - Mylan, Inc. - Pinnacle Biologics, Inc. - Stryker Corporation - Terumo Corporation - W. L. Gore & Associates, Inc. For more information visit http://www.researchandmarkets.com/research/wm...rug_device
Next Resistance Level for Abbott Laboratories (ABT) is $39.88
Comtex SmarTrend(R) - Tue Mar 18, 10:44AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $39.37 today and has reached the first level of resistance at $39.69. Investors may be interested in a cross of the next upside pivot targets of $39.88 and $40.39.
Abbott Announces FDA Approval of Its Supera® Stent to Treat People with Peripheral Artery Disease
PR Newswire - Fri Mar 28, 10:58AM CDT
Abbott today announced that its Supera® Peripheral Stent System has received U.S. Food and Drug Administration (FDA) approval to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). PAD occurs when fat and cholesterol buildup causes arteries outside of the heart to narrow, which reduces blood flow to parts of the body, most commonly the legs. The disease affects 12 to 20 percent of Americans age 65 or older and can cause leg pain, in addition to increasing the risk of heart attack or stroke.1
Baxter Hits 52-Week High on Planned Business Split-Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 9:24AM CDT
BAX expects to complete splitting up the business in mid-2015
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Baxter Splitting In Effort To 'Unlock Trapped Value'
at Investor's Business Daily - Thu Mar 27, 5:41PM CDT
Baxter International (BAX) announced Thursday that it will split its biopharma and medical-products businesses into two separate companies by mid-2015, jump-starting its lagging stock with a move that seemed to surprise Wall Street. "We and many...
Baxter splitting into 2 separate businesses
By LINDA A. JOHNSON - AP - Thu Mar 27, 1:32PM CDT
TRENTON, N.J. (AP) — Following a rival's lead, Baxter International Inc. said it's planning a breakup into two health care companies as it tries to boost innovation and profitability and reward shareholders.
Baxter International to Split In Response to Macro Challenges
at The Street - Thu Mar 27, 7:05AM CDT
Baxter International's split was also characterized as a response to diverging dynamics between the two businesses and a rapidly changing macro-environment.
Abbott Laboratories (ABT) Crosses Pivot Point Resistance at $38.71
Comtex SmarTrend(R) - Wed Mar 26, 10:44AM CDT
Shares of Abbott Laboratories (NYSE:ABT) have bullishly opened above the pivot of $38.39 today and have reached the first resistance level of $38.71. Analysts will be watching for a cross of the next upside pivot targets of $39.01 and $39.63.
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Is J&J's Forgotten Half About to Take Off?
Peter Stephens, The Motley Fool - Motley Fool - Tue Mar 25, 5:30PM CDT
Johnson & Johnson is often cited as the biggest pharmaceutical company in the world, but it also generates a significant amount of revenue from medical device products. Let's take a deep dive into this division and focus on the key areas that...
RBCC to Increase Investment in 3D Bioprinting Innovation
Business Wire - Tue Mar 25, 9:18AM CDT
As demand for new cellular research innovations continues to soar worldwide, Rainbow Biosciences, the biotechnology division of Rainbow Coral Corp. (OTCBB: RBCC), is increasing its investment in the marketing and development of a breakthrough 3D bioprinting technology.
The Global Generic Drugs Industry Experienced Average Growth Over the Last Five Years and is Expected to Reach Approximately US $335.8 Billion in 2017
M2 - Tue Mar 25, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2st8r/top_five_generic) has announced the addition of the "Top Five Generic Drugs Companies: Performance, Strategies and Competitive Analysis" report to their offering. Top companies are making strategic acquisitions to expand their global footprint, together with taking advantage of established business and expertise gained through the acquired company. The report provides detailed insight into the performance of the top five generic drug companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered. The fragmented generic drugs industry includes producers of medications whose patent or marketing rights have expired. The industry includes drugs from all therapeutic areas: central nervous system, cardiovascular drugs, oncology drugs, and others. A combination of factors such as technology innovations, patent expiration, aging population, and changing lifestyles substantially affect market dynamics. In this study, the author profiles the following five companies with detailed competitive assessments: - Abbott Laboratories - Novartis AG - Mylan Inc. - Teva Pharmaceuticals Ind. Ltd. - Watson Pharmaceuticals Inc As indicated in the study, the Asia Pacific (APAC) region holds good growth potential. India is expected to play an increasing role in the global economy as demand from a growing population continues to drive consumption for generic drugs. Major pharmaceuticals companies are planning to invest in the Asian markets to gain the market share for generic drugs. This study provides industry leaders with a competitive benchmarking of the world's top five generic drug companies. The study provides up-to-date information on the market share, profit margins, capabilities, and business strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis, and insight, critical to the development and implementation of effective marketing and sales plans. For more information visit http://www.researchandmarkets.com/research/q2...ve_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Top Five Global Medical Device Companies: The Global Medical Device Industry is Expected to Reach Approximately $302 Billion in 2017 with A CAGR of 6.1% over Next Five Years
M2 - Tue Mar 25, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl6bwk/top_five_global) has announced the addition of the "Top Five Global Medical Device Companies: Performance, Strategies and Competitive Analysis" report to their offering. The report provides detailed insight into the performance of the top five medical devices companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered. The medical device industry is highly fragmented and consists of surgical and infection control devices, general medical devices, cardiovascular, home healthcare, and other devices. North America dominates this industry. In this study, the author thoroughly profiles the following five companies with detailed competitive assessments: - Abbott Laboratories - Boston Scientific - Covidien Plc. - Johnson & Johnson - Medtronic, Inc. The research indicates that technological advancement, growing population, and increasing aging population is expected to provide opportunities for the industry players. Technology advancement may lead to nanotechnology applications and use of surgical robots as a new segment entering into the medical device industry, and this is further expected to improve the prospects for the device market. India and China are expected to be the driving countries for growth. North America is expected to witness a considerable growth for the medical device industry over the forecast period. The cardiovascular segment represents good growth during the forecast period. This study is intended to provide industry leaders with a concise overview of the world's top five global medical equipment companies. This discussion is limited to a comparative analysis of the subject companies, their geographic footprints, financial metrics, market performance, marketing and corporate strategies, and SWOT analysis. It excludes the equipment such as orthopedic, invitro diagnostic, technical aids, and such other equipment. For more information visit http://www.researchandmarkets.com/research/cl...ive_global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT November 22nd Options Begin Trading
at The Street - Mon Mar 24, 11:09AM CDT
Investors in Abbott Laboratories saw new options become available today, for the November 22nd expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 243 days until expiration the...
This Generic Drug Threat Won't Go Away
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Mar 22, 12:35PM CDT
Editor's Note: In the video, Michael Douglass refers to a quote from Mylan's president. The quote is actually from the president of Mylan's North American operations, Anthony Mauro. The Fool regrets the error. "The unintended consequences of...
China Adalimumab Market Investigation Report with 2018 Forecasts Now Available at ChinaMarketResearchReports.com
PRWeb - Fri Mar 21, 9:31PM CDT
Adalimumab is a TNF (tumor necrosis factor) inhibiting antiinflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA.
After Yesterday's Decline of 1.44%, Abbott Laboratories Offers Investors Better Value
Comtex SmarTrend(R) - Thu Mar 20, 3:54PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $38.78 to a high of $39.64. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $39.04 on volume of 10.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Sucampo's NDA Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:05PM CDT
Sucampo Pharma recently announced that its New Drug Application (NDA) for the liquid formulation of Amitiza will not be filed in the second half of 2014.
Drug Device Combination Products Market Report 2013 - 2019: Forecasts & Trends for the $US100 Billion Market
M2 - Tue Mar 18, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wmt3kk/drug_device) has announced the addition of the "Drug Device Combination Products Market Report 2013 - 2019: Forecasts & Trends for the $US100 Billion Market" report to their offering. The global drug device combination products market was valued at USD 66 billion in 2012 and is expected to grow at a CAGR of 7.9% from 2013 to 2019, to reach an estimated value of USD 115 billion in 2019. This report studies the global market for drug device combination products from the perspective of product types. The market is thus segmented into drug eluting stents, infusion pumps, bone graft implants, photodynamic therapy, wound care combination devices, inhalers, transdermal patches and others including intraocular implants and drug eluting beads. The market for all these product segments is also analyzed for four major geographic regions namely North America, Europe, Asia and the rest of the world (RoW) regions. The markets for all these segments is analyzed and estimated in USD billion. Each of the segments have been analyzed on the basis of its current and future market size for the period 2011 to 2019, in terms of revenue generation in USD billion, considering 2011 and 2012 as the base years. The compounded annual growth rate (%CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. A competitive landscape, mapping all the market players and their respective market shares for 2012 are provided in this report for drug eluting stents and infusion pumps. A chapter on recommendations for existing and new entrants is also provided in this report. Drug Device Combination Products Market: - Drug Eluting Stents - Infusion Pumps - Photosensitizers - Orthopedic Combination Products - Wound Care Combination Products - Inhalers - Transdermal Patches - Intraocular Implants and Drug Eluting Beads Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Drug Device Combination Products, by Type, Size and Forecast, 2011-2019 (USD Billion) Chapter 5 Global Drug Device Combination Products, by Geography, 2011 - 2019 (USD Million) Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories - Alcon, Inc. - Allergan, Inc. - Arrow International, Inc. - Bausch & Lomb, Inc. - Boston Scientific Corporation - C.R. Bard, Inc. - CareFusion Corporation - Covidien PLC - Ethicon, Inc. - Medline Industries, Inc. - Medtronic, Inc. - Mylan, Inc. - Pinnacle Biologics, Inc. - Stryker Corporation - Terumo Corporation - W. L. Gore & Associates, Inc. For more information visit http://www.researchandmarkets.com/research/wm...rug_device
Next Resistance Level for Abbott Laboratories (ABT) is $39.88
Comtex SmarTrend(R) - Tue Mar 18, 10:44AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $39.37 today and has reached the first level of resistance at $39.69. Investors may be interested in a cross of the next upside pivot targets of $39.88 and $40.39.
